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Coexistence of Chronic Lymphocytic Thyroiditis with Papillary 
Thyroid Carcinoma: Clinical Manifestation and Prognostic 
Outcome
The study aimed to identify the clinical characteristics of coexisting chronic lymphocytic 
thyroiditis (CLT) in papillary thyroid carcinoma (PTC) and to evaluate the influence on 
prognosis. A total of 1,357 patients who underwent thyroid surgery for PTC were included. 
The clinicopathological characteristics were identified. Patients who underwent total 
thyroidectomy (n = 597) were studied to evaluate the influence of coexistent CLT on 
prognosis. Among the total 1,357 patients, 359 (26.5%) had coexistent CLT. In the CLT 
group, the prevalence of females was higher than in the control group without CLT 
(P < 0.001). Mean tumor size and mean age in the patients with CLT were smaller than 
without CLT (P = 0.040, P = 0.047, respectively). Extrathyroidal extension in the patients 
with CLT was significantly lower than without CLT (P = 0.016). Among the subset of 597 
patients, disease-free survival rate in the patients with CLT was significantly higher than 
without CLT (P = 0.042). However, the multivariate analysis did not reveal a negative 
association between CLT coexistence and recurrence. Patients with CLT display a greater 
female preponderance, smaller size, younger and lower extrathyroidal extension. CLT is not 
a significant independent negative predictive factor for recurrence, although presence of 
CLT indicates a reduced risk of recurrence.
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INTRODUCTION
Papillary thyroid carcinoma (PTC) is the most common form of 
thyroid cancer, and its incidence is rapidly increasing in many 
countries (1). Chronic lymphocytic thyroiditis (CLT) is the most 
common inflammatory disorder of the thyroid gland. Although 
the frequency of CLT varies widely from 0.5%-38%, the coexis-
tence of CLT and PTC has been reported in several studies since 
first reported in 1955 (2-6).
 The prevalence of CLT in patients with PTC has been reported 
to be significantly higher than with benign thyroid tumors (5). 
Patients with CLT are believed to be at higher risk for PTC com-
pared with patients without CLT (7). The presence of CLT in pa-
tients with PTC has been associated with better prognostic out-
come, lower recurrence rate and less aggressive disease at the 
time of surgery (3, 4, 8-10). However, it has been conversely re-
ported that the coexistence of CLT has no protective effect on 
patient outcome (11). Thus, the pathogenesis and prognostic out-
come of the coexistence of PTC and CLT remains controversial.
 A number of investigators have reported that clinicopatho-
logic factors, including age, gender, tumor size, multi-focality, 
capsular invasion, extrathyroidal extension and lymph node 
(LN) metastasis are related to the prognosis of PTC (12-14). To 
investigate that coexistent CLT might contribute to a better prog-
nosis in patients with PTC, the present study was undertaken 
to evaluate the prevalence of coexistent CLT in a population of 
PTC patients firstly and determine the association, if any, of 
CLT with clinicopathological parameters that are indicative of 
better prognosis at the time of initial diagnosis secondarily. The 
final goal of the study was to determine whether CLT is an inde-
pendent risk factor for the prognosis of PTC.
MATERIALS AND METHODS
Patients for first study arm
Patients with PTC who underwent thyroid surgery between 
January 2005 and December 2006 at Yonsei University Hospital, 
Seoul, Korea were enrolled. All patients underwent pre-opera-
tive ultrasonography and fine needle aspiration cytology (FNAC) 
of the primary tumor, and were diagnosed with PTC pathologi-
cally. Of these patients, excluding patients with another subtype 
of thyroid carcinoma and a variant of PTC, and patients who 
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had been diagnosed with CLT or any thyroid disease before be-
ing diagnosed with PTC were also excluded to prevent selection 
bias, because they had more opportunity for early detection of 
PTC that could lead to better treatment outcomes. A total 1,357 
patients who received initial treatment for PTC at our institu-
tion and whose medical records were accessible for review as 
included in the first study arm to identify clinical characteristics 
of coexistent CLT in PTC patients at the time of surgery. 
Patients for second study arm
Among these 1,357 patients, those who were lost to follow-up, 
who had a history of the coexistence of another cancer, and who 
revealed lateral neck LN metastasis or distant metastasis at the 
time of surgery were excluded. Five hundred ninety seven con-
secutive patients with PTC who underwent total thyroidectomy 
with prophylatic ipsilateral central compartment node dissec-
tion followed by immediate 131I remnant ablation were enrolled 
in the second study arm to evaluate the influence on prognostic 
outcome of coexistent CLT in PTC patients. 
Clinicopathological parameters
Patient data were collected by retrospective medical record re-
view. Patient demographics (age and gender), histopathologi-
cal findings (tumor size, extrathyroidal extension, multifocality, 
LN metastasis and presence of CLT), preoperative laboratory 
finding (thyroid stimulating hormone [TSH], anti-thyroglobulin 
[Tg] autoantibody and anti-microsomal autoantibody) and 
clinical outcomes (loco-regional recurrences and distant me-
tastasis) were analyzed. Pathologic staging was defined accord-
ing to the Tumor, LN, and Metastasis (TNM) classification sys-
tem based on the 6th edition of the UICC/AJCC TNM classifica-
tions. In addition, two well-established prognosis classification 
systems of differentiated thyroid cancer - the low/high risk 
group determination based on the Age, Metastasis, Extent of 
disease, Size (AMES) stage system (15) and the Metastasis, Age 
at presentation, Completeness of surgical resection, Invasion 
(extrathyroidal extension), Size (MACIS) formula-based scor-
ing system (16) - were used to analyze various clinicopathologi-
cal parameters. The systems have established that high scores 
are strongly correlated with a poor prognosis. Serum anti-mi-
crosomal and anti-Tg antibody analysis was performed by ra-
dioimmunoassay with commercial kits (Brahms, Berlin, Ger-
many). TSH level was determined by an immunoradiometric 
assay (Coat-ACount, TSH IRMA; DPC, Los Angeles, CA, USA). 
The analytical sensitivity of the assay for anti-microsomal anti-
body, anti-Tg and TSH was 5.5, 5.5, and 0.3 IU/mL, respectively. 
The intraassay coefficients of variation ranged from 2.9%-4.5%, 
2.0%-7.5%, and 1.9%-5.8%, respectively. The reference ranges 
for both anti-microsomal antibody and antithyroglobulin were 
< 60 IU/mL and for TSH 0.3-5.0 mL/L.
Definition of CLT 
The diagnosis of CLT was obtained from a review of the patho-
logic slides by one pathologist. Pathologically proven CLT was 
defined as the presence of diffuse lymphoplasmacytic infiltrate, 
oxyphilic cells, formation of lymphoid follicles with germinal 
centers and atrophic changes in the area of normal thyroid tis-
sue. Only peri-tumoral lymphocytic infiltration was not consid-
ered as CLT (2, 3, 9, 17).
Initial treatment for PTC
At our institution, thyroid resection consisted of total thyroidec-
tomy and less than total thyroidectomy. The definition of “less 
than total thyroidectomy” is specified by unilateral thyroid lo-
bectomy, ipsilateral total and contralateral partial thyroidecto-
my, and ipsilateral total and contralateral subtotal thyroidecto-
my. Thyroid lobectomy with isthmusectomy was performed 
only when the following criteria were met: the cancer was an 
intrathyroidal, unifocal micro-carcinoma (< 1 cm), with no cer-
vical lymph node involvement. In other cases, total thyroidec-
tomy was performed. Ipsilateral central compartment node 
dissection was performed in all cases. If the patients have evi-
dence of lateral lymph node metastasis in preoperative evalua-
tion, Modified radical neck dissection was performed. The 
choice of surgical extension was based on ATA guidelines (18). 
During thyroid resection, only central compartment lymph 
nodes (CCLN) located in the ipsilateral site of the primary tu-
mor were dissected prophylatically. The CCLN or level VI in-
cluded the pretracheal, paratracheal, prelaryngeal, perithyroi-
dal nodes, and lymph nodes located along the recurrent laryn-
geal nerve. The central compartment was delimited superiorly 
by the hyoid bone, inferiorly by the substernal notch, laterally 
by the median portion of the carotid sheath, and dorsally by the 
prevertebral fascia. Recurrent laryngeal nerves and parathyroid 
glands were identified and preserved in all cases. The proce-
dures were performed by the same surgical team. If patients 
had evidence of lateral LN metastasis in preoperative evalua-
tion, modified radical neck dissection was performed. Radioac-
tive iodine remnant ablation was performed within 6 weeks af-
ter surgery. Indication for radioiodine ablation in this cohort of 
patients was based on ATA guidelines (18). A 131I whole body 
scan was taken on day 2 following radioiodine therapy. All pa-
tients received thyroid-stimulating hormone suppression treat-
ment with levothyroxine according to ATA guidelines. Patient 
follow-up was based on physical examination, neck ultrasound 
(US), and serum Tg measurement at intervals of 3 or 6 months. 
Statistical analyses
Statistical analysis was performed using SPSS (version 14.0; 
SPSS, Chicago, IL, USA). Continuous data are represented as 
mean ± standard deviation. To compare continuous variables, 
age, tumor size and mean, MACIS scores according to CLT sta-
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tus were tested using an independent t-test. The association be-
tween CLT (present or absent) and prognostic variables was as-
sessed using a chi-squared test or Fisher’s exact test for gender, 
extrathyroidal extension, multifocality, LN metastasis, TNM 
and AMES stage. The Kaplan-Meyer method with a log-rank 
test was used to account for recurrence and disease free rates 
during the follow-up period. Statistically significant variables 
based on univariate analysis were included in a multivariate 
analysis using a binary logistic regression test. With regard to 
the results, P values were two-sided throughout and the statisti-
cal significance was defined as P < 0.05.
Ethics statement 
This study was approved by the institutional review board of 
Severance Hospital, Yonsei University College of Medicine in 
Seoul, Korea (IRB number: 4-2011-0879). All participants gave 
their written informed consent.
RESULTS
Comparison of initial clinical manifestation between PTC 
patients with/without CLT (First study arm)  
Among the 1,357 patients, there were 181 men and 1,176 wom-
en. Mean age was 45.53 yr. The mean tumor size was 1.08 ± 0.77 
cm. Multifocality, extrathyroidal extension and LN metastasis 
were detected in 450 (33.2%), 752 (55.4%) and 619 patients 
(45.6%), respectively. Three hundred fifty nine (26.5%) of 1,357 
patients with PTC had co-existing CLT. Based on univariate 
analysis, the mean age of patients with and without CLT was 
44.50 ± 10.65 and 45.90 ± 11.68 yr, respectively (P = 0.047). Pre-
dominance of female gender was observed in patients with CLT 
compared to patients without CLT (P = 0.001). The mean tumor 
size was smaller in patients with CLT than patients without CLT 
(1.01 ± 0.66 cm vs 1.10 ± 0.81 cm, respectively; P = 0.040). The 
prevalence of extrathyroidal extension was higher in patients 
without CLT (P = 0.016). There was no statistically significant 
difference in the prevalence of operation methods, multifocali-
ty and TNM stage between the two groups (P = 0.094, 0.845, and 
0.781, respectively). The rate of total LN metastasis was not sig-
nificantly different in patients with and without CLT patients 
(P = 0.294). There was no difference in the prevalence of central 
LN metastasis and lateral LN metastasis between the two groups 
(P = 0.322 and 0.252, respectively). Table 1 summarizes the re-
sults of the univariate analyses.
Association of prognostic outcomes with coexisting CLT in 
PTC patients (Second study arm)
The clinical and pathological parameters of the second study 
cohort are summarized in Table 2. When total thyroidectomy 
patients results were compared with the results from the total 
patient population, the prevalence of women and small tumor 
size were evident in the group of patients who had PTC with 
CLT (P = 0.001 and 0.035, respectively), although there was no 
difference in extrathyroidal extension and age between the two 
groups (P = 0.724 and 0.153, respectively). There was no differ-
ence in the prevalence of LN metastasis, multifocality and TNM 
stage between the two groups (P = 0.784, 0.316, and 0.620, re-
spectively). However, LN metastasis ratio (metastatic LN num-
Table 1. Initial clinical manifestation of total patients who underwent thyroid surgery 
for PTC at the time of surgery
Parameters
All patients  
(n = 1,357) 
(100%)
PTC without 
CLT  
(n = 998) 
(73.5%)
PTC with  
CLT  
(n = 359) 
(26.5%)
P 
value
Age at operation (yr) 45.53 ±
11.43
45.90 ±
11.68
44.50 ±
10.65
0.047 
Gender
   Male
   Female
 
   181 (13.3)
1,176 (86.7)
 
169 (16.9)
829 (83.1)
 
12 (3.3)
347 (96.7)
0.001 
Operation method
   Less than total with CCND*
   Total thyroidectomy with 
      CCND
   MRND†
 
   272 (20.0)
   893 (65.8)
 
   192 (14.1)
 
210 (21.0)
640 (64.1)
 
148 (14.8)
 
  62 (17.3)
253 (70.5)
 
  44 (12.3)
0.094 
 
 
Maximum tumor size (cm) 1.08 ± 0.77 1.10 ± 0.81 1.01 ± 0.66 0.040 
Extrathyroidal extension    752 (55.4) 573 (57.4) 179 (49.9)  0.016 
Multifocality    450 (33.2) 333 (33.4) 117 (32.6) 0.845 
Total LN metastasis    619 (45.6) 464 (46.5) 155 (43.2) 0.294 
Central LN metstasis    598 (44.1) 448 (44.9) 150 (41.8) 0.322 
Lateral LN metastasis    192 (14.1) 148 (14.8)   44 (12.3) 0.252 
TNM stage
   I
   II
   III
   IV
 
   824 (60.9)
     4 (0.3)
   424 (31.3)
 102 (7.5)
 
602 (60.4)
  3 (0.3)
313 (31.4)
78 (7.8)
 
222 (62.0)
  1 (0.3)
111 (31.0)
24 (6.7)
0.781 
*Central compartment node dissection; †Total thyroidectomy with CCND + modified 
radical neck dissection.
Table 2. Clinicopathologic characteristics of patients who underwent total thyroidec-
tomy with CCND for PTC and follow up for 5 yr
Parameters
PTC without CLT  
(n = 402)
PTC with CLT  
(n = 195)
P value
Age at operation (yr)   48.56 ± 11.02 47.24 ± 9.84 0.153 
Gender
   Male
   Female
 
  70 (17.4)
332 (82.6)
 
   7 (3.6)
 188 (96.4)
0.001 
Maximum tumor size (cm)   1.12 ± 0.77   0.99 ± 0.61 0.035 
Extrathyroidal extension 236 (58.7)  111 (56.9) 0.724 
Multifocality 137 (34.1)    75 (38.5) 0.316 
LN* metastasis 142 (35.3)    66 (33.8) 0.784 
LN metastasis number   0.90 ± 1.59   0.93 ± 1.76 0.846 
Dissected LN number   4.22 ± 2.59   7.03 ± 3.86 0.001 
LNM ratio† (%)   21.76 ± 34.41   13.97 ± 25.17 0.005 
TNM stage
   I
   II
   III
   IV
 
227 (56.5)
  2 (0.5)
163 (40.5)
10 (2.5)
 
 107 (55.2)
0 (0)
   84 (43.3)
   3 (1.5)
0.620 
Recurrence (5-yr f/u) 20 (5.0)    3 (1.5) 0.042 
Follow up duration (months) 58.12 ± 8.12 58.55 ± 7.19 0.527 
*Lymph node; †Metastatic lymph node number/Dissected Lymph node number.
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ber/dissected LN number) was lower in patients with CLT 
compared to patients without CLT (P = 0.001). The recurrence 
rate in the patients with CLT (1.5%) was lower than that in with-
out CLT (5.0%) (P = 0.042). 
 Evaluation of the expected prognostic outcome using the 
AMES (15) clinical staging system and the MACIS scoring sys-
tem (16) was also performed. With the AMES staging system, 
the proportion of high-risk group of patients with PTC alone 
was higher than that of patients with PTC and CLT (31.3% and 
21.0%, respectively; P = 0.009). Using the MACIS scoring sys-
tem, the proportion of the high-risk group of patients with PTC 
alone was also higher than that of patients with PTC and CLT. 
Patients with PTC alone exhibited a higher mean score (4.89 vs 
4.74; P = 0.049) and a higher percentage (15.4% vs 7.2%) of the 
patients scoring ≥ 6 on the MACIS scoring system (P = 0.004; 
Table 3).
Diagnosis of recurrence and result of survival
All patients in whom recurrence was suspected were confirmed 
using cytology and/or histology. During the mean 58-month 
follow-up period in the PTC with CLT group, three (1.5%) of 195 
patients experienced recurrence and all of the recurrent diseas-
es occurred at the ipsilateral lateral LN. Comprehensive neck 
dissection followed by high-dose radioactive iodine remnant 
ablation therapy was performed in all of these patients, and 
none have died at the time of the present evaluation. Of the pa-
tients in PTC without CLT with a mean 58-month follow-up pe-
riod, a total of 20 (5.0%) have experienced recurrence, the main 
locations were the regional LN (18 patients; 3 patients =  ipsilat-
eral central LN, 15 patients = ipsilateral lateral LN), and 2 pa-
tients had distant lung metastasis. Comprehensive neck dissec-
tion followed by high-dose radioactive iodine remnant ablation 
therapy was performed in all of these patients, and none have 
died at the time of the present evaluation. Patients with PTC 
and CLT tended to have a better prognosis compared with that 
of patients with PTC alone. Disease free survival (DFS) rate in 
the patients with CLT was significantly higher than that without 
CLT during follow-up period (log-rank = 4.11, P = 0.042; Fig. 1). 
Table 3. Evaluation of the expectant prognostic outcome using the AMES clinical stag-
ing system and the MACIS scoring system
Staging
All patients  
(n = 597)
PTC without CLT 
(n = 402)
PTC with CLT 
 (n = 195)
P value
AMES stage
   Low risk
   High risk
 
430 (72.0)
167 (28.0)
 
276 (68.7)
126 (31.3)
 
154 (79.0)
  41 (21.0)
0.009
MACIS score
   Mean
  < 6
  ≥ 6
 
4.84 ± 0.92
521 (87.3)
  76 (12.7)
 
4.89 ± 0.96
340 (84.6)
  62 (15.4)
 
4.74 ± 0.81
181 (92.8)
14 (7.2)
 
0.049
0.004
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Fig. 1. Disease free survival rate in patients who underwent total thyroidectomy with 
central compartment node dissection. 
Di
se
as
e 
fre
e 
su
rv
iv
al
 ra
te
Di
se
as
e 
fre
e 
su
rv
iv
al
 ra
te
Months after operation Months after operation
Patients with lymph node metastasis Patients without lymph node metastasis
0 20 40 60 80 0 20 40 60 80
100
90
80
70
60
50
100
90
80
70
60
50
PTC without CLT: 88.03% PTC without CLT: 98.85%
PTC with CLT: 96.97% PTC with CLT: 99.22%
P = 0.0379 P = 0.7314
Fig. 2. Disease free survival rate in patients with and without lymph node metastasis. 
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DFS was evaluated according to the presence or absence of LN 
metastasis at the time of surgery. Especially in PTC patients with 
central LN metastasis, DFS was significantly higher in patients 
with CLT compared with those without CLT (log-rank = 4.31, 
P = 0.038; Fig. 2).
 We separately analyzed the outcomes for lower-risk group 
and high-risk groups by AMES stage and MACIS scoring sys-
tems. In lower-risk patients, DFS was significantly different in 
patients with CLT compared with those without CLT (P = 0.009 
and P = 0.018, respectively). But, there were no significant dif-
ferences in high-risk patients with CLT compared with those 
without CLT by AMES stage and MACIS scoring system (P =  
0.778 and P = 0.456, respectively). 
Analysis of the association of clinical recurrence with 
various clinicopathological parameters
Based on univariate analysis, LN metastasis (P = 0.001, odds 
ratio [OR] = 9.676) and CLT (P = 0.042, OR = 0.298) were ob-
served in patients with recurrence compared with patients with-
out recurrence. However, gender (i.e., prevalence of females), 
extrathyroidal extension, age, tumor size and multifocality were 
not significantly different based on the univariate analysis be-
tween the two groups (Table 4). However, based on multivari-
ate analysis, only LN metastasis (P = 0.001, OR = 9.278) was ob-
served in patients with recurrence compared with patients with-
out recurrence. The multivariate analysis did not show a nega-
tive association between the coexistence of CLT and recurrence. 
Analysis of correlation between pathologic and laboratory 
diagnosis about CLT
We analyzed the CLT patients separately to evaluate the corre-
lation between pathologic diagnosis and laboratory finding. 
CLT patients who were confirmed pathologically were divided 
into group A (anti-Tg Ab and anti-microsomal Ab were all nega-
tive) and group B (anti-Tg Ab positive or anti-microsomal Ab 
positive). In group A patients, CLT was confirmed by pathologi-
cal examination but laboratory examination was negative, while 
CLT was confirmed in group B patients by pathological and lab-
oratory examinations. The clinical and pathological parameters 
are summarized in Table 5. There was no statistically significant 
difference in age, gender, size, prevalence of extrathyroidal ex-
tension, multifocality, LN metastasis, TNM stage and recurrenc-
es between the two groups. 
DISCUSSION
PTC is the most common cancer involving the thyroid gland, 
with a 10-yr relative survival rate of 93% (19). Although the prog-
nosis for patients with PTC is excellent, patient age at diagnosis, 
stage of PTC, tumor size, presence of cervical node or distant 
metastasis, extrathyroidal extension, delay in diagnosis, extent 
of thyroidectomy and postoperative radioiodine ablation influ-
ence patient outcome (20). The frequency of co-existing CLT in 
patients with PTC has been variously reported to range from 
0.5%-38% (3-5). This variability results from differences in pa-
tient selection (gender, age and history of autoimmune thyroid 
disorder) or indication for thyroidectomy, differences of the 
histopathologic definition for CLT, environmental factors (his-
tory of radiation exposure), genetic background and geograph-
ic factors (e.g., iodine intake) (3-5). Presently, CLT was defined 
as the presence of lymphoid follicles with germinal centers, atro-
phic changes in the area of normal thyroid parenchyma and 
Table 4. Univariate and multivariate analysis for recurrence with the statistically significant variables
Variables
Univariate analysis Multivariate analysis
OR 95% CI P value OR 95% CI P value
Gender (female vs male) 0.400 0.153-1.048 0.102  0.502 0.180-1.402 0.188
Age ≤ 45 vs > 45 0.897 0.328-2.109 0.827 1.117 0.453-2.750 0.810
Size ≤ 1 cm vs > 1 cm 1.692 0.734-3.900 0.277 1.084 0.435-2.703 0.862
Multifocality 0.967 0.403-2.320 0.941 1.150 0.460-2.875 0.765
Extrathyroidal extension 2.095 0.814-5.392 0.135 1.510 0.550-4.146 0.424
Lymph node metastasis 9.676 3.246-28.842 0.001 9.278 3.025-28.456 0.001
PTC with CLT vs without CLT 0.298 0.088-0.993 0.042 0.338 0.095-1.201 0.094
Table 5. Clinicopathologic characteristics of patients with confirmed CLT pathologi-
cally with/without laboratory examination
Parameters
Group A  
n = 31 (15.9%)
Group B 
n = 164 (84.1%)
P value
Age at operation (yr) 49.16 ± 9.08 46.87 ± 9.97 0.236 
Gender
   Male
   Female
 
   1 (3.2)
   30 (96.8)
 
  6 (3.7)
158 (96.3)
0.905 
Maximum tumor size (cm)   0.84 ± 0.37   1.01 ± 0.64 0.149 
Extrathyroidal extension    19 (61.3)   92 (56.1) 0.694 
Multifocality    12 (38.7)   63 (38.4) 0.975 
LN metastasis    10 (32.3)   56 (34.1) 0.839 
TNM stage
   I
   III
   IV
 
   15 (48.4)
   14 (45.2)
   2 (6.5)
 
  93 (56.7)
  70 (42.7)
  1 (0.6)
0.052 
Recurrence 0 (0)   3 (1.8) 1.000 
Group A, Chronic lymphocytic thyroiditis was confirmed by pathological examination 
without laboratory examination; Group B, Chronic lymphocytic thyroiditis was con-
firmed by pathological and laboratory examination.
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excluded only lymphocytic infiltration within or surrounding a 
tumor focus. Using this definition, 26.5% of the PTC patients 
had CLT in our study. This frequency of CLT with PTC is consis-
tent with recent reports in patients undergoing thyroidectomy 
(3, 4, 9, 21).
 The autoimmune response to thyroid-specific antigens in 
patients with CLT may be involved in the destruction of cancer 
cells expressing thyroid-specific antigen in PTC, thus prevent-
ing recurrences and improving survival. However, it remains 
unclear whether or not the presence of CLT affects the biologic 
behavior of PTC, although the association between CLT and 
PTC has been reported in many studies (2-6, 8, 9, 11).
 Bagnasco et al. (22) reported a higher proportion of cytotoxic 
T cells with natural killer (NK)-like or lymphokine-activated killer 
activity in PTC infiltrating T cells compared to those occurring 
in autoimmune thyroid disorders (Hashimoto’s thyroiditis and 
Graves’ disease). In addition to the primarily cell-mediated in-
flammatory reaction observed in PTC. Lucas et al. (23) demon-
strated that more humoral-mediated immune reactions occur 
with PTC (80% of PTC cases) than with other thyroid neoplasms 
or autoimmune thyroid disorders. This study suggests that a hu-
moral-specific tumor immune response consisting of an im-
munoglobulin/complement-mediated reaction may also occur 
with PTC. Therefore, both humoral and cytotoxic T cell-medi-
ated destruction involved in autoimmune thyroid disorders 
may have a direct or indirect effect in patients with PTC associ-
ated with CLT (24). The Fas-mediated apoptotic pathway acti-
vated by Fas and Fas ligand is expressed in follicular cells in pa-
tients with CLT, and might be involved in the destruction of tu-
mor cells in patients with Hashimoto’s thyroiditis, which is sim-
ilar to CLT histopathologically (25). Kimura et al. (26) reported 
that interleukin-1 secreted by infiltrating lymphocytes inhibits 
human thyroid carcinoma cell growth. Therefore, destruction 
of tumor cells via humoral and cytotoxic T cell-mediated im-
mune mechanisms might be related to the favorable effect of 
CLT on PTC. In a large retrospective study conducted by Kim et 
al. (3), the presence of CLT in patients with PTC was associated 
with a smaller tumor size, younger age, female predominant 
and a reduced risk of recurrence; these findings echo those of 
Kebebew et al. (3, 4).
 Based on univariate analysis in our study, PTC in patients with 
CLT was significantly associated with younger age, female gen-
der, smaller tumor size, a lower incidence of extrathyroidal ex-
tension and a lower incidence of LN metastasis ratio compared 
to patients without CLT. If our hypothesis that coexistent CLT 
might contribute to a better prognosis in patients with PTC is 
correct, patients with more severe CLT would have better prog-
nostic factors of PTC. However, there were no significant differ-
ences in the clinicopathologic parameters evaluating the corre-
lation between the pathologic and laboratory findings among 
patients with pathologically confirmed CLT.
 Emerging literature suggests a protective effect of CLT in pa-
tients with PTC. In a large retrospective study, Kashima et al. (9) 
reported a 0.7% cancer specific mortality and a 95% relapse-free 
10-yr survival rate in patients with CLT, compared to a 5% mor-
tality and 85% relapse-free 10-yr survival rate without CLT. These 
findings were similar to another study (6). Singh et al. (8) iden-
tified a positive correlation between CLT in patients with PTC 
and DFS and overall survival, and concluded that patients with 
PTC in the presence of CLT had a more favorable clinical out-
come in terms of recurrence and mortality. Also, in our study, 
98.46% relapse-free 5-yr survival rate in patients with CLT was 
evident, compared to a 95.02% relapse-free 5-yr survival rate in 
patients without CLT. 
 In our study, coexisting CLT was assumed to be associated 
with better prognostic factors, such as younger age, smaller tu-
mor size, female and lower extrathyroidal extension at the time 
of initial surgery than in patients with PTC alone. However, the 
statistical significance was not verified by multivariate analysis 
(Table 4). Furthermore, we analyzed the outcomes separately 
for the lower-risk group and high-risk group by AMES stage and 
MACIS scoring system. Although, there were significant differ-
ences in lower-risk patients with CLT compared with those with-
out CLT by AMES stage and MACIS scoring system, there were 
no significant difference in high-risk patients with CLT compared 
with those without CLT by AMES stage and MACIS scoring sys-
tem. So, CLT was not an independent negative predictive factor. 
This result was most likely because most of the patients with CLT 
had other good prognostic factors, such younger age and female 
gender. The results echo those of Kebebew et al. (4). 
 This study has some potential limitations. The study was based 
on patients who had suspected malignant nodules and under-
went thyroid surgery. This would introduce a selection bias into 
the study population. Moreover, since many patients with CLT 
are not treated surgically, we were unable to account for the true 
incidence of CLT. A prospective cohort study of the general pop-
ulation should be performed to overcome these limitations.
 In conclusion, we found a relatively common occurrence of 
CLT in patients with PTC. Compared to patients with PTC with-
out CLT, patients with CLT were younger, predominantly female, 
had a small tumor size and a lower extrathyroidal extension 
rate at the time of surgery, which are the most important and 
well-known prognostic variables for thyroid cancer mortality. 
Although coexistent CLT in PTC patients reduced the risk of re-
currence, especially in patients with LN metastasis at the time 
of surgery, CLT was not an independent predictive factor for re-
currence.
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